Cancer Biological Therapy Market Size Worth USD 199652.8 Million , Globally, By 2030 At 7.5% CAGR.

The latest market report published by Credence Research, Inc. “Global Cancer Biological Therapy Market: Growth, Future Prospects, and Competitive Analysis, 2022 – 2030. The global demand for cancer biological therapy was valued at USD 111945.8 Million in 2022 and is expected to reach USD 199652.8 Million in 2030, growing at a CAGR of 7.5% between 2023 and 2030.

Cancer Biological Therapy Market Drivers refer to the various factors that propel the growth and advancement of this specialized field within oncology. One crucial driver is the increasing prevalence of cancer worldwide, necessitating innovative treatment options beyond traditional chemotherapy and radiation therapy. The rising incidence of different types of cancers prompts researchers and pharmaceutical companies to invest heavily in developing biological therapies, leading to a surge in market demand. Moreover, technological advancements have significantly enhanced our understanding of cancer biology, enabling scientists to identify specific molecular targets for therapeutic interventions. This has paved the way for the development of targeted therapies that can selectively attack cancer cells while sparing healthy tissues, thus minimizing side effects commonly associated with conventional treatments

The cancer biological therapy market, also known as immunotherapy or targeted therapy, represents a transformative approach to cancer treatment. This market focuses on harnessing the body’s natural defense mechanisms or targeting specific molecular pathways involved in cancer growth to combat the disease. Biological therapies include monoclonal antibodies, adoptive cell therapies, cancer vaccines, and immune checkpoint inhibitors, among others.

One of the key strengths of biological therapies is their potential for precision medicine, as they can be tailored to target specific types of cancer or even individual genetic profiles. This has led to remarkable advancements in oncology, with improved treatment outcomes, fewer side effects, and enhanced overall quality of life for cancer patients.

The cancer biological therapy market has witnessed significant growth due to ongoing research and development efforts, a deeper understanding of the immune system’s role in cancer, and the approval of novel therapies by regulatory agencies. These therapies have demonstrated remarkable success in treating a variety of cancers, including melanoma, lung cancer, and certain types of leukemia.

Furthermore, the market continues to evolve with the exploration of combination therapies, which involve using biological agents in conjunction with other treatment modalities such as chemotherapy or radiation therapy. This synergistic approach aims to enhance treatment efficacy and broaden the spectrum of cancers that can be effectively managed.

Browse 245 pages report Cancer Biological Therapy Market By Therapeutic Approach (Monoclonal Antibodies (mAbs), Tyrosine Kinase Inhibitors (TKIs), Immune Checkpoint Inhibitors, Cytokines, Cancer Vaccines, Gene Therapy, Oncolytic Viruses, Others) By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Leukemia and Lymphoma, Melanoma, Prostate Cancer, Other Cancer Types) – Growth, Future Prospects & Competitive Analysis, 2016 – 2030

 List of the prominent players in the Cancer Biological Therapy Market:

  • F. Hoffmann-La Roche Ltd
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd
  • Sanofi
  • Pfizer Inc
  • GSK Plc
  • Novartis AG
  • Bayer AG
  • Merck & Co. Inc
  • Sun Pharmaceutical Industries Ltd

The cancer biological therapy market offers a wide range of key offerings that play a pivotal role in the treatment and management of cancer. These offerings include:

Monoclonal Antibodies (mAbs): Monoclonal antibodies are engineered proteins designed to target specific cancer cells or molecules involved in cancer growth. They are a cornerstone of cancer immunotherapy and are available for various cancer types.

Immune Checkpoint Inhibitors: These drugs block certain proteins on the surface of immune cells or cancer cells, enhancing the immune system’s ability to recognize and attack cancer. Immune checkpoint inhibitors have revolutionized cancer treatment for several malignancies.

CAR-T Cell Therapy: Chimeric Antigen Receptor T-cell therapy involves genetically modifying a patient’s T cells to express a receptor that recognizes cancer cells. CAR-T therapies have shown remarkable success in treating some blood cancers.

Cancer Vaccines: Therapeutic cancer vaccines stimulate the patient’s immune system to target cancer cells. These vaccines may be specific to certain cancer antigens or neoantigens created by mutations in the patient’s tumor.

Adoptive Cell Therapy: This approach involves harvesting and modifying a patient’s own immune cells, such as T cells, outside the body before infusing them back into the patient. CAR-T cell therapy is one example of adoptive cell therapy.

Targeted Therapies: Targeted therapies inhibit specific molecules or pathways involved in cancer growth. They are designed to disrupt cancer’s signaling mechanisms while sparing healthy cells.

Cytokine Therapy: Cytokines, such as interleukins and interferons, are used to boost the immune system’s response to cancer. They have been used in the treatment of certain cancers like melanoma and renal cell carcinoma.

Bispecific Antibodies: Bispecific antibodies can simultaneously target two different molecules, such as a cancer cell and an immune cell, increasing their specificity and potency in cancer treatment.

Biosimilars: Biosimilars are biologic products that are highly similar to already approved biological therapies. They provide more affordable options for patients while maintaining therapeutic efficacy.

Supportive Care: Supportive care medications and therapies are offered to manage side effects and improve the overall well-being of cancer patients undergoing biological treatments.

Why to Buy This Report-

  • The report provides a qualitative as well as quantitative analysis of the global Cancer Biological Therapy Market by segments, current trends, drivers, restraints, opportunities, challenges, and market dynamics with the historical period from 2016-2020, the base year- 2021, and the projection period 2022-2028.
  • The report includes information on the competitive landscape, such as how the market’s top competitors operate at the global, regional, and country levels.
  • Major nations in each region with their import/export statistics
  • The global Cancer Biological Therapy Market report also includes the analysis of the market at a global, regional, and country-level along with key market trends, major player analysis, market growth strategies, and key application areas.

Browse Full Report:


Related Report:

Related Report:

Browse Our Blog:

About Us –

Credence Research is a viable intelligence and market research platform that provides quantitative B2B research to more than 10,000 clients worldwide and is built on the Give principle. The company is a market research and consulting firm serving governments, non-legislative associations, non-profit organizations, and various organizations worldwide. We help our clients improve their execution in a lasting way and understand their most imperative objectives. For nearly a century, we’ve built a company well-prepared for this task.

Contact Us:

Office No 3 Second Floor, Abhilasha Bhawan, Pinto Park, Gwalior [M.P] 474005 India

Leave a Reply

Your email address will not be published.